STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDX
  4. [Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Celldex (CLDX) EVP & CSO awarded 115,000-share stock option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. Executive VP & Chief Scientific Officer Tibor Keler received an incentive stock option grant covering 115,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.

According to the vesting terms, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. After this grant, Keler holds options for 115,000 underlying shares directly.

Positive

  • None.

Negative

  • None.
Insider KELER TIBOR
Role EXECUTIVE VP & CSO
Type Security Shares Price Value
Grant/Award Incentive Stock Option (right to buy) 115,000 $0.00 --
Holdings After Transaction: Incentive Stock Option (right to buy) — 115,000 shares (Direct, null)
Footnotes (1)
  1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Option grant size 115,000 shares Incentive stock option underlying common shares
Exercise price $34.09 per share Incentive stock option strike price
Expiration date June 25, 2036 Option expiration
First vesting date June 25, 2027 25% of option vests
Post-grant option holdings 115,000 options Total options held following transaction
Incentive Stock Option financial
"Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
2021 Omnibus Equity Incentive Plan financial
"granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"
vesting financial
"25% vest on June 25, 2027 and the remainder vest quarterly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: "34.0900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KELER TIBOR
(Last)(First)(Middle)
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
(Street)
HAMPTON NEW JERSEY 08827
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EXECUTIVE VP & CSO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy)(1)$34.0906/25/2026(1)A115,00006/25/2027(2)06/25/2036Common Stock115,000$0115,000D
Explanation of Responses:
1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Sam Martin, attorney-in-fact for Tibor Keler06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Celldex (CLDX) disclose about Tibor Keler in this Form 4?

Celldex disclosed that Executive VP & CSO Tibor Keler received an incentive stock option to acquire 115,000 shares of common stock at $34.09 per share, expiring June 25, 2036, as part of equity compensation.

How many Celldex (CLDX) shares are covered by Tibor Keler’s new option grant?

The new option grant covers 115,000 shares of Celldex common stock. This entire amount is tied to a single incentive stock option award granted under the company’s 2021 Omnibus Equity Incentive Plan.

What is the exercise price of Tibor Keler’s Celldex (CLDX) stock options?

The exercise price of the incentive stock option is $34.09 per share. This is the fixed price at which Keler can purchase Celldex common stock once the option vests and is exercisable.

When do Tibor Keler’s newly granted Celldex (CLDX) options vest?

Twenty-five percent of the option vests on June 25, 2027. The remaining 75% vests in equal quarterly installments over the next 12 quarters, creating a multi-year vesting schedule linked to continued service.

When do Tibor Keler’s Celldex (CLDX) stock options expire?

The incentive stock option granted to Tibor Keler expires on June 25, 2036. After that expiration date, any unexercised portion of the option will no longer be available for him to exercise.

Under which plan were Tibor Keler’s Celldex (CLDX) options granted?

The option was granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan provides a framework for issuing stock-based awards like options to executives and employees as part of their compensation.